New Brunswick adds Albrioza for ALS to its public health plan
New Brunswick is reimbursing, through its public health insurance program, the cost of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine)…
Articles by Marisa Wexler, MS
In ALS, motor neurons’ molecule misplacement is widespread: Study
It’s long been known that some molecules are misplaced in the nerve cells that progressively die in amyotrophic lateral…
Polygenic scoring system may help to predict ALS risk
A new genetic risk score that takes hundreds of different genetic variations into account may help predict who’s most likely…
ALS research into miR-155 blockers advances to animal testing stage
Work into developing molecules that block microRNA-155 (miR-155) as potential treatments for amyotrophic lateral sclerosis (ALS) has advanced to…
Specific mRNA molecule may be useful as biomarker in ALS
A messenger RNA (mRNA) molecule that provides the instructions for a protein involved in glutamate signaling is not edited as…
Gout medication decreases risk of ALS and other diseases: Study
Allopurinol and carvedilol, two medications respectively used to manage gout and high blood pressure, significantly reduce the chances of developing…
Some sporadic ALS patients have mutation causing other diseases
A sizable portion of people with sporadic amyotrophic lateral sclerosis (ALS) carry a genetic mutation known to cause other…
Early clinical trial testing gut microbe transplants in ALS patients
An early clinical trial is testing whether fecal microbiota transplants (FMT) — a procedure that aims to introduce healthy bacteria…
AAN 2023: Radicava leads to better long-term survival in ALS
Radicava (edaravone) significantly prolongs long-term survival for people with amyotrophic lateral sclerosis (ALS), according to an analysis of…
AAN 2023: ALS treatments ID’d in HEALEY head toward Phase 3 tests
It’s been nearly three years since the HEALEY platform clinical trial started and, so far, two promising experimental treatments for…